Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: A prospective population-based study

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Cotoi, Ovidiu S ^a   Manjer, Jonas ^b   Hedblad, Bo ^b   Engström, Gunnar ^b   Melander, Olle ^b   Schiopu, Alexandru ^b,c  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Cardiovascular disease; CRP; Inflammation; Mortality; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROCALCITONIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA SKIN CANCER; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECTUM CANCER; SEX DIFFERENCE; SKIN CANCER; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT CANCER;

CALCITONIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLASMA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SURVIVAL ANALYSIS;

EID: 84881306597     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-180     Document Type: Article

References (37)

1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138. 10.1016/j.jacc.2009.09.009, 2834169, 19942084.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
3. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006, 445:245-255. 10.1016/j.abb.2005.08.008, 16171772.
4. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012, 308:788-795. 10.1001/jama.2012.9624, 22910756.
5. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012, 32:1119-1136. 3349285, 22493341.
6. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011, 48:155-170. 10.3109/10408363.2011.599831, 22035340.
7. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, Goh E, Cho B, Park M. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev 2012, 21:2076-2086. 10.1158/1055-9965.EPI-12-0611, 23136255.
8. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg cohort study, 1984-1998. Clin Chem 2008, 54:335-342. 10.1373/clinchem.2007.100271, 18156284.
9. Becker KL, Nylen ES, White JC, Muller B, Snider RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004, 89:1512-1525. 10.1210/jc.2002-021444, 15070906.
10. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518. 10.1016/0140-6736(93)90277-N, 8094770.
11. Snider RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997, 45:552-560.
12. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000, 26:S148-S152.
13. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, ProHOSP Study Group Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066. 10.1001/jama.2009.1297, 19738090, ProHOSP Study Group.
14. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001, 86:396-404. 10.1210/jc.86.1.396, 11232031.
15. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010, 159:253-264. 10.1111/j.1476-5381.2009.00433.x, 2825349, 20002097.
16. Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, Becker KL. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res 2011, 60:203-207. 10.1007/s00011-010-0255-8, 20953970.
17. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002, 30:1112-1117. 10.1097/00003246-200205000-00025, 12006810.
18. Schiopu A, Hedblad B, Engstrom G, Struck J, Morgenthaler NG, Melander O. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med 2012, 272:484-491. 10.1111/j.1365-2796.2012.02548.x, 22530956.
19. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993, 233:45-51. 10.1111/j.1365-2796.1993.tb00647.x, 8429286.
20. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000, 17:299-307.
21. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Publ Health 2011, 11:450.
22. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001, 30:S30-S34. 10.1093/ije/30.suppl_1.S30, 11759848.
23. Charbonney E, Terrettaz M, Vuilleumier N, Lambert JF. Acute chest syndrome in sickle cell disease and acute respiratory distress syndrome--from pathophysiology to therapy. Rev Med Suisse 2006, 2:2852-2857.
24. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001, 18:79-87.
25. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638. 10.1056/NEJMoa021423, 12711737.
26. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, Boyle P. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008, 122:155-164. 10.1002/ijc.23033, 17893872.
27. Walter MA, Meier C, Radimerski T, Iten F, Kranzlin M, Muller-Brand J, de Groot JW, Kema IP, Links TP, Muller B. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer 2010, 116:31-40.
28. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004, 100:2462-2469. 10.1002/cncr.20275, 15160353.
29. Shomali W, Hachem R, Chaftari AM, Jiang Y, Bahu R, Jabbour J, Raad S, Al Shuaibi M, Al Wohoush I, Raad I. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?. Cancer 2012, 118:5823-5829. 10.1002/cncr.27602, 22605389.
30. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000, 248:171-183. 10.1046/j.1365-2796.2000.00742.x, 10971784.
31. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998, 63:854-865.
32. Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998, 26:1001-1006. 10.1097/00003246-199806000-00015, 9635646.
33. Redl H, Schiesser A, Togel E, Assicot M, Bohuon C. Possible role of TNF on procalcitonin release in a baboon model of sepsis. Shock 2001, 16:25-27. 10.1097/00024382-200116010-00005, 11442311.
34. Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, Li Q, Tamarkin L, White JC. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 2000, 14:73-78. 10.1097/00024382-200014010-00013, 10909897.
35. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183. 10.1172/JCI31537, 1857251, 17476347.
36. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816. 10.1053/j.gastro.2011.01.057, 21530747.
37. Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 2011, 11:451-464. 10.2174/156800911795538066, 3540985, 21247378.